Rheumatoid Arthritis Pathophysiology and Management | Osmosis

Osmosis explains rheumatoid arthritis as a systemic autoimmune inflammatory disease that predominantly affects the joints but can involve other organs. The video outlines the autoimmune triggers, citrullination of antigens, formation of autoantibodies, pannus development, cytokine networks, and the spectrum of therapies from DMARDs to biologics and anti inflammatory drugs.

Overview of rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disorder of autoimmune origin that most noticeably targets synovial joints, leading to progressive joint destruction if not treated. The condition is typically triggered by a combination of genetic susceptibility and environmental factors, such as smoking or exposure to certain pathogens. In susceptible individuals, environmental factors can cause citrullination of self proteins, creating modified antigens that may be recognized as foreign by the immune system. This sets the stage for an autoimmune response in which T helper cells activate B cells, producing autoantibodies that circulate in the blood and reach joints, where inflammatory cascades drive tissue injury.

"Rheumatoid arthritis is a chronic inflammatory autoimmune disorder that primarily targets the joints" - Osmosis

Joints and synovial pathology

Healthy synovial joints have an articular cartilage surface and a synovial membrane that produces lubrication. In RA, the immune response leads to synovial hyperplasia and the formation of a thickened, inflamed pannus that invades cartilage and bone. This pannus is rich in fibroblasts, macrophages, and inflammatory cells that release proteolytic enzymes and cytokines, promoting cartilage breakdown and bone erosion. Cytokines such as interferon gamma and interleukin 17 recruit additional inflammatory cells, amplifying joint damage. A key molecular step is the increased expression of RANKL on T cells, which binds to RANK on osteoclasts and stimulates bone resorption.

"Pannus is a thickened inflamed synovial membrane that damages cartilage and bone" - Osmosis

Autoantibodies and immune complexes

Persistent immune activation in RA involves autoantibodies such as rheumatoid factor (RF) and anti citrullinated peptide (CCP) antibodies. These autoantibodies form immune complexes in the synovial fluid, activating the complement system and perpetuating inflammation. The citrullinated antigens—produced when arginine is converted to citrulline—are targeted by CCP antibodies, and this autoantibody response is a hallmark of RA in many patients. Autoantibodies help link genetic susceptibility to environmental triggers and joint pathology.

"RF and CCP antibodies form immune complexes that fuel inflammation" - Osmosis

Cytokine networks and systemic effects

RA is characterized by a network of inflammatory cytokines, including TNF alpha, interleukin 1, interleukin 6, and interleukin 17. These cytokines drive synovial cell proliferation, immune cell recruitment, and systemic effects. Inflammation can escape the joints and contribute to extra articular manifestations such as fever, anemia, lung involvement, skin nodules, and vasculitis. The liver increases hepcidin in response to inflammatory signals, which lowers serum iron and can contribute to fatigue, while joint inflammation can promote angiogenesis, further sustaining immune cell influx.

Clinical features and diagnosis

RA typically presents with symmetric involvement of multiple joints, especially small joints of the hands and feet, with swelling, warmth, redness, and morning stiffness. Over time, joints may become deformed, particularly at the metacarpophalangeal joints, with characteristic deformities such as boutonniere and swan neck. Diagnosis involves serology for RF and CCP antibodies, imaging showing joint space narrowing, soft tissue swelling, and bone erosions, and a clinical assessment of symmetric joint involvement. Imaging and laboratory tests together guide disease activity assessment and treatment decisions.

Treatment and management

Long term management focuses on disease modifying antirheumatic medications (DMARDs) such as methotrexate, hydroxychloroquine, and sulfasalazine, which suppress inflammation and slow joint damage. Biologic disease modifying agents or biologics target specific immune pathways: some suppress T cell activity, others B cells, and others block cytokines like TNF, interleukin 1, or interleukin 6. In acute flares, non steroidal anti inflammatory drugs (NSAIDs) and short courses of glucocorticoids provide symptomatic relief. Early and aggressive treatment aims to achieve remission or low disease activity and prevent irreversible joint damage and systemic complications.

Putting it together

RA is a systemic inflammatory disorder of autoimmune origin that causes progressive symmetric joint destruction and can involve multiple organ systems. Diagnosis rests on serology for rheumatoid factor and anti citrullinated peptide antibodies and characteristic imaging findings, while management relies on DMARDs and biologics to slow disease progression and reduce symptoms.

"DMARDs and biologics can suppress inflammation and slow joint damage" - Osmosis